Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

× No keyword cloud information.

15 in total

Review 1. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.

Authors: S K Martin; P Diamond; S Gronthos; D J Peet; A C W Zannettino
Journal: Leukemia Date: 2011-06-03 Impact factor: 11.528

2. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Authors: S Colla; P Storti; G Donofrio; K Todoerti; M Bolzoni; M Lazzaretti; M Abeltino; L Ippolito; A Neri; D Ribatti; V Rizzoli; E Martella; N Giuliani
Journal: Leukemia Date: 2010-09-02 Impact factor: 11.528

3. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors: Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal: Blood Date: 2015-04-01 Impact factor: 22.113

4. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.

Authors: Annunziata De Luisi; Arianna Ferrucci; Addolorata M L Coluccia; Roberto Ria; Michele Moschetta; Emanuela de Luca; Luisa Pieroni; Michele Maffia; Andrea Urbani; Giulia Di Pietro; Attilio Guarini; Girolamo Ranieri; Paolo Ditonno; Simona Berardi; Antonella Caivano; Antonio Basile; Nicola Cascavilla; Silvana Capalbo; Giovanni Quarta; Franco Dammacco; Domenico Ribatti; Angelo Vacca
Journal: Clin Cancer Res Date: 2011-02-09 Impact factor: 12.531

5. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Authors: Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman
Journal: Br J Haematol Date: 2007-11-09 Impact factor: 6.998

6. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

Authors: M Teresa Cibeira; María Rozman; Marta Segarra; Esther Lozano; Laura Rosiñol; Maria C Cid; Xavier Filella; Joan Bladé
Journal: Cytokine Date: 2008-01-04 Impact factor: 3.861

7. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

Authors: Jing Zhang; Martin Sattler; Giovanni Tonon; Clemens Grabher; Samir Lababidi; Alexander Zimmerhackl; Marc S Raab; Sonia Vallet; Yiming Zhou; Marie-Astrid Cartron; Teru Hideshima; Yu-Tzu Tai; Dharminder Chauhan; Kenneth C Anderson; Klaus Podar
Journal: Cancer Res Date: 2009-06-09 Impact factor: 12.701

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Review 1. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.

2. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

3. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

4. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.

5. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

6. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

7. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

8. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

9. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.

10. ERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1.

1. Hypoxia inducible factor-1 alpha and multiple myeloma.

Review 2. Metabolic Vulnerabilities in Multiple Myeloma.

Review 3. Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.